FDA INDICATIONS AND USAGE1,2

Dojolvi™ is a medium-chain triglyceride indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

APPROVAL CRITERIA1,2

1. Patient has a molecularly confirmed diagnosis of a long-chain fatty acid oxidation disorder based on at least TWO of the following (a, b, or c):
   a. Disease-specific elevations of acylcarnitines on a newborn blood spot or in plasma; OR
   b. Enzyme activity assay (in cultured fibroblasts or lymphocytes) below the lower limit of the normal reference range for the reporting laboratory; OR
   c. Genetic testing demonstrating pathogenic mutation in a gene associated with long-chain fatty acid oxidation disorders AND;
2. Is being prescribed by or in consultation with an endocrinologist or metabolic disease specialist AND;
3. The prescriber has submitted the patient’s weight and total prescribed daily caloric intake AND;
4. The dose does not to exceed 35% of Daily Caloric Intake.

DENIAL CRITERIA1

1. Failure to meet approval criteria OR;
2. Patient is concurrently using another medium chain triglyceride product.

CAUTIONS1

- Avoid co-administration of Pancreatic Lipase Inhibitors due to potential for reduced clinical effect.

DURATION OF APPROVAL

- Initial Approval: up to 3 months
- Reauthorization Approval: up to 12 months

QUANTITY LIMIT

Dojolvi™ Criteria
Version: 1
Original: 10/08/20
Approval: 11/20/20
Effective: 1/11/21
ALASKA MEDICAID
Prior Authorization Criteria

- 30 days – dose does not exceed 35% of the patient’s caloric intake

REFERENCES / FOOTNOTES: